0O14 Stock Chart & Stats
€142.00
€2.15(1.54%)
At close: 4:00 PM EDT
€142.00
€2.15(1.54%)
Day’s Range― - ―
52-Week Range€100.70 - €148.50
Previous CloseN/A
Volume31.69K
Average Volume (3M)45.59K
Market Cap
€60.87B
Enterprise Value€74.31K
Total Cash (Recent Filing)€1.96B
Total Debt (Recent Filing)€12.30B
Price to Earnings (P/E)25.7
Beta1.34
Next Earnings
Nov 12, 2026EPS Estimate
2.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.45
Shares Outstanding129,242,250
10 Day Avg. Volume29,699
30 Day Avg. Volume45,589
Financial Highlights & Ratios
PEG Ratio-3.35
Price to Book (P/B)1.86
Price to Sales (P/S)2.53
P/FCF Ratio22.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€143.50Price Target Upside1.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)8.28
Revenue Forecast (FY)€21.35B
Bulls Say, Bears Say
Bulls Say
Durable MarginsSustained high gross and operating margins provide structural resilience across business cycles. Strong margins support reinvestment in R&D and capital, fund margin-accretive initiatives in Life Science and Electronics, and help preserve profitability even if top-line growth slows.
Manageable LeverageModerate and improving leverage gives the company financial flexibility to fund organic growth, M&A, and cyclical headwinds without dangerously high interest burdens. A healthier balance sheet supports investment in long-term projects and reduces refinancing risk.
Improving Free Cash FlowRecent improvement in free cash flow enhances the company's ability to self-fund R&D, capex, and shareholder distributions. Stronger FCF trends reduce dependence on external financing and enable strategic allocation of capital over the medium term.
Bears Say
Weak Revenue TrendA weakening top line erodes operating leverage and limits the scope to expand absolute profits without margin recovery. Prolonged revenue decline pressures investment capacity, makes funding growth initiatives harder, and raises questions about demand or competitive positioning.
Declining Returns On EquityFalling ROE signals the company is generating less profit per unit of shareholder capital. That may reflect weaker product mix, pricing pressure, or heavier capital intensity, and it reduces the long-term efficiency of reinvested earnings for shareholders.
Moderate Cash ConversionOnly moderate conversion of earnings into cash limits internal funding for capex, M&A, and dividends. Reliance on less-than-robust cash conversion increases exposure to working capital swings and could necessitate external financing for larger strategic investments.
0O14 FAQ
What was Merck KGaA’s price range in the past 12 months?
Merck KGaA lowest share price was €100.70 and its highest was €148.50 in the past 12 months.
What is Merck KGaA’s market cap?
Merck KGaA’s market cap is €60.87B.
When is Merck KGaA’s upcoming earnings report date?
Merck KGaA’s upcoming earnings report date is Nov 12, 2026 which is in 91 days.
How were Merck KGaA’s earnings last quarter?
Merck KGaA released its earnings results on Aug 06, 2026. The company reported €2.16 earnings per share for the quarter, beating the consensus estimate of €2.026 by €0.134.
Is Merck KGaA overvalued?
According to Wall Street analysts Merck KGaA’s price is currently Undervalued.
Does Merck KGaA pay dividends?
Merck KGaA does not currently pay dividends.
What is Merck KGaA’s EPS estimate?
Merck KGaA’s EPS estimate is 2.07.
How many shares outstanding does Merck KGaA have?
Merck KGaA has 129,242,250 shares outstanding.
What happened to Merck KGaA’s price movement after its last earnings report?
Merck KGaA reported an EPS of €2.16 in its last earnings report, beating expectations of €2.026. Following the earnings report the stock price went up 0.172%.
Which hedge fund is a major shareholder of Merck KGaA?
Currently, no hedge funds are holding shares in GB:0O14
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merck KGaA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€143.50 (1.06% Upside)
€143.50 (1.06% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.29%
12-Months-Change
Fundamentals
Return on Equity
1.58%
Trailing 12-Months
Asset Growth
7.49%
Trailing 12-Months
Company Description
Merck KGaA
Merck KGaA is a German science and technology company with operations divided into three core segments: Life Science, Healthcare, and Electronics. The Life Science division supplies essential tools, chemicals, and equipment to academic research institutions, biotechnology firms, pharmaceutical manufacturers, and various industrial sectors. It also offers specialized process development expertise, such as continuous bioprocessing for drug manufacturers, provides a range of testing kits, reagents, and services, and develops solutions for analyzing environmental samples like air, water, and soil. Furthermore, this segment aids in assessing nutritional value and identifying quality control issues. In its Healthcare segment, the company is involved in the entire lifecycle of prescription drugs and biopharmaceuticals, from initial discovery and development through manufacturing and marketing. Its therapeutic focus areas include oncology, neurology and immunology, fertility, endocrinology, cardiovascular diseases, diabetes, thyroid disorders, and multiple sclerosis. This segment also produces general medicines, injection devices, and software for disease monitoring. The Electronics division delivers critical materials for the semiconductor and display industries. It also specializes in surface design, providing delivery systems and services, along with a variety of surface solutions for applications such as cosmetics, effect pigments, and other functional materials. Merck KGaA is also actively engaged in strategic partnerships. These include in-licensing agreements with Debiopharm International SA for developing treatments for head and neck cancer, with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for metastatic colorectal cancer drug candidates, and with Abbisko Therapeutics Co. Ltd. for therapies targeting tenosynovial giant cell tumors. Additionally, the company is involved in collaborations focused on discovering and developing targeted protein degraders against critical oncogenic proteins. Founded in 1668 and headquartered in Darmstadt, Germany, Merck KGaA operates as a subsidiary of E. Merck KG.
0O14 Stock 12 Month Forecast
Average Price Target
€143.50
▲(1.06% Upside)
Technical Analysis
Evotec
―
Fresenius SE & Co. KGaA
―
Sartorius
―
Dermapharm Holding SE
―
Siemens Healthineers AG
―